| Iris Löw-Friedrich |
Iris Löw-Friedrich is currently the President & Chief Executive Officer at Zogenix, Inc. She is also the Chairman-Supervisory Board at Evotec SE, the Director at PhRMA Foundation, an Independent Member-Supervisory Board at Fresenius SE & Co. KGaA, and a Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main. In her former positions, Dr. Löw-Friedrich served as the Chairman at Transcelerate Biopharma, Inc. from 2015 to 2017. She was also the Director-Supervisory Board at Heidelberg Pharma AG from 2007 to 2010. Additionally, she held the role of Vice President-Clinical Development at Hoechst AG from 1992 to 2000, Vice President-Global Projects at BASF SE from 2000 to 2001, Head-Research & Development at UCB Pharma GmbH from 2001 to 2009, and Head-Global Clinical Management & VP at Aventis Pharma AG. She also worked as a Vice President-Clinical Development at Hoechst Marion Roussel, Inc. and BASF Pharma. Prior to her industry roles, she worked as a Staff Physician-Internal Medicine at Frankfurt University Medical School. Dr. Löw-Friedrich obtained her doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main in 1985. |
